About 7% of 428 Omicron COVID-19 survivors who were health-sciences students at a Saudi Arabian college reported persistent symptoms, notably loss of smell or taste, for more than 28 days.
A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, is tied to a 61% reduction in COVID-19 hospitalization and a 58% lower rate of long COVID.
On average, the pandemic caused low-income countries to experience an average progress loss of 16.5% across all health indicators, whereas high-income countries have seen losses as low as 3%, the authors said.
